Investor News / RNS

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Cristian Gradinaru has joined its technical team as a Senior PKPD Modeller.   Cristian holds a PhD from the Technical University of Copenhagen, Denmark in Stochastic Modelling of Biological Systems, and an MSc from Stanford University, USA in Biophysics. He...

Read More

The Company considers that the award of options linked to the Company’s performance is critical to the incentivisation of its employees and to ensure that there is alignment between management and shareholders.   To this end, the Company today confirms that it has agreed to issue 850,000 share options (the “Options”) over ordinary shares of 0.4p each in the Company (“Ordinary Shares”) to its non-director employees, under...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, the Servier Group (“Servier”), an international pharmaceutical company headquartered in France.  Cancer is one of Servier’s priority therapy areas and it has a particular focus on immunotherapies and monoclonal antibodies...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Tim Corn will join the Company’s board as an Independent Non-Executive Director from 1 April 2022.   Dr Tim Corn qualified in medicine at King's College Hospital and, after becoming honorary Consultant and Senior Lecturer, joined the pharmaceutical industry in...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions today made a presentation regarding its Interim results for the six months ended 31 December 2021, using the Investor Meet Company platform.  The slide deck used in the presentation will be posted on the Company’s website at https://www.physiomics.co.uk/resources/  ...

Read More

Q: The tie-up with Tabula Rasa and their DosemeRx platform was considered to be a potential game changer for Physiomics.  Now that Tabula Rasa have advised the market that they are selling their interest in DosemeRx does this in any way diminish this commercial potential The answer to this was also covered during the main presentation however just to say that DoseMeRx remains interested in working...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, will issue its interim results for the six months ended 31 December 2021 on Monday 7 March 2022. The Company is further pleased to announce that Dr Jim Millen will provide a live presentation relating to its interim results via the Investor Meet Company...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, Ankyra Therapeutics (“Ankyra”). Ankyra is a Boston-based biotech focused on improving both the safety and efficacy of cancer treatment by using their proprietary anchored immunotherapy platform. Ankyra recently announced a...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, announces that Dr Paul Harper is standing down from the role of Non-Executive Chairman and as a Director of the Company with immediate effect.  Dr Harper has served the Company since 2004 as Non-Executive Director, and since 2007 as Chairman, and the Board...

Read More